<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="105804">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01797562</url>
  </required_header>
  <id_info>
    <org_study_id>SP 12 7NEW 401</org_study_id>
    <nct_id>NCT01797562</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of T.R.U.E. Test Allergens in Children an Adolescents</brief_title>
  <official_title>Clinical Evaluation of T.R.U.E. Test Panel 3.2 in Children and Adolescents (PREA II)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allerderm</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allerderm</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the performance and safety of seven T.R.U.E. Test Panel allergens in subjects
      6-17 years of age with suspected contact dermatitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the diagnostic performance (primary) and safety (secondary) of seven T.R.U.E.
      Test Panel allergens; Gold sodium thiosulfate, Hydrocortisone-17-butyrate, Bacitracin,
      Parthenolide, Methyldibromoglutaronitrile, Disperse blue 106, and Bronopol in pediatric
      subjects 6-17 years of age with suspected contact dermatitis based on symptoms and clinical
      history.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Frequency and characterization of positive reactions per allergen.</measure>
    <time_frame>Day 21</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of late or persistent reactions, irritation, adhesion, subject-reported itching or burning, and adverse events.</measure>
    <time_frame>Day 21</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Allergic Contact Dermatitis</condition>
  <arm_group>
    <arm_group_label>T.R.U.E. Test Panel 3.2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T.R.U.E. Test Panel allergens; Gold sodium thiosulfate, Hydrocortisone-17-butyrate, Bacitracin, Parthenolide, Methyldibromoglutaronitrile, Disperse blue 106, and Bronopol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>T.R.U.E. Test Panel 3.2</intervention_name>
    <description>Surgical tape containing 12 polyester allergen patches.</description>
    <arm_group_label>T.R.U.E. Test Panel 3.2</arm_group_label>
    <other_name>Gold sodium thiosulfate</other_name>
    <other_name>Hydrocortisone-17-butyrate</other_name>
    <other_name>Bacitracin</other_name>
    <other_name>Parthenolide</other_name>
    <other_name>Methyldibromoglutaronitrile</other_name>
    <other_name>Disperse blue 106</other_name>
    <other_name>Bronopol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptoms and history potentially consistent with allergic contact dermatitis

          -  Children and adolescents 6-17 years of age, in general good health

          -  Adolescent females 15 years of age or older (or with menarche) must consent to a
             urine pregnancy test; urine test results must be negative for study inclusion

          -  Informed consent must be signed and understood by subject.  If underage, informed
             consent must be signed and understood by parent or legal guardian, consistent with
             all institutional, local and national regulations

        Exclusion Criteria:

          -  Topical corticosteroid treatment during the last 7 days on or near the test area.

          -  Systemic treatment with corticosteroids or other immunosuppressives during the last 7
             days.

          -  Subjects currently receiving (or received during the previous 3 weeks) other
             investigational drugs, treatments or devices, or participating in another clinical
             study

          -  Treatment with ultraviolet (UV) light (including tanning) during the previous 3 weeks

          -  Acute dermatitis outbreak or dermatitis on or near the test area on the back

          -  Subjects unable to comply with activity restrictions (e.g. protecting test panels
             from excess moisture due to showering or vigorous activity)

          -  Subjects unable or unwilling to comply with multiple return visits

          -  Female subjects 15 years of age (or with onset of menarche) and older unable to
             consent to a urine pregnancy test, or those with a positive pregnancy test
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cory Dunnick, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anschutz Health and Wellness Center, University of Colorado, Aurora, CO</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joseph Fowler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dermatology Specialists, Louisville, KY</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lawrence Eichenfield, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rady Children's Hospital, San Diego</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patricia Norris, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kim Sullivan</last_name>
    <phone>602-225-0595</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Rady Children's Hospital</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann Funk, RN</last_name>
      <phone>858-576-1700</phone>
      <phone_ext>4295</phone_ext>
    </contact>
    <investigator>
      <last_name>Lawrence Eichenfield, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Anschutz Health and Wellness Center, University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa Derian, RN</last_name>
      <phone>303-724-9155</phone>
    </contact>
    <investigator>
      <last_name>Cory Dunnick, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dermatology Specialists</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maureen Beyel, RN</last_name>
      <phone>502-582-7546</phone>
    </contact>
    <investigator>
      <last_name>Joseph Fowler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristin Morton</last_name>
      <phone>503-494-4662</phone>
    </contact>
    <investigator>
      <last_name>Patricia Norris, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 17, 2013</lastchanged_date>
  <firstreceived_date>February 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Contact dermatitis</keyword>
  <keyword>Eczema</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Contact</mesh_term>
    <mesh_term>Dermatitis, Allergic Contact</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bacitracin</mesh_term>
    <mesh_term>Bronopol</mesh_term>
    <mesh_term>Sodium thiosulfate</mesh_term>
    <mesh_term>Cortisol succinate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Parthenolide</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Hydrocortisone-17-butyrate</mesh_term>
    <mesh_term>Gold Sodium Thiosulfate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
